Why the study?
Does intravenous ribavirin improve survival or viral shedding in patients with influenza virus-associated fulminant myocarditis?
Does intravenous ribavirin improve survival or viral shedding in patients with influenza virus-associated fulminant myocarditis?
Intravenous ribavirin terminated viral shedding in influenza-associated fulminant myocarditis, but did not prevent fatal outcomes in this small case series.
Answers are grounded in this paper and cite their sources.
May terminate shedding without preventing death in this series; leaves open ribavirin efficacy in influenza myocarditis, needing controlled trials.
We studied three patients with influenza virus-associated fulminant myocarditis; one was infected by type B and the others by type A influenza virus. In one patient, dissemination of type A (H1N1) virus to the myocardium was demonstrated, and viremia complicated the clinical course despite the use of oral amantadine HCl and ribavirin aerosol. All patients were treated with iv ribavirin, two initially and the third after viremia was detected during hyperacute rejection of a cardiac transplant. No significant adverse effects could be directly attributed to therapy, and viral shedding abruptly terminated coincident with its use; however, both patients treated shortly after onset of myocarditis died. The third required support by an artificial heart, and died 8 mo later. Immunotyping of myocardial tissues in two cases revealed an initial predominance of T helper cells. Serial endomyocardial biopsies available from one of these demonstrated a subsequent marked decrease in the T helper cell population as inflammation and necrosis subsided during and following therapy.
No takes yet. Share an insight, caveat, or question.
Ray et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: